Showing results (291-300 of 718) with videos related to
Sort By:
Pageof 72
The Journal of Peptide Research : Official Journal of the American Peptide Society|May 3, 2002
Crystal structure of biphalin sulfate: a multireceptor opioid peptideJ L Flippen-Anderson, J R Deschamps, C George, et al.Bioconjugate Chemistry|November 1, 1994
Multivalent melanotropic peptide and fluorescent macromolecular conjugates: new reagents for characterization of melanotropin receptorsS D Sharma, M E Granberry, J Jiang, et al.Journal of Medicinal Chemistry|May 1, 1985
Cyclic melanotropins. 9. 7-D-Phenylalanine analogues of the active-site sequenceW L Cody, M Mahoney, J J Knittel, et al.International Journal of Peptide and Protein Research|November 1, 1984
Cyclic melanotropins. Part VII: Modified ring structures--synthesis and biological activityM Lebl, W L Cody, B C Wilkes, et al.Journal of Medicinal Chemistry|January 20, 2000
Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligandJ Alfaro-Lopez, T Okayama, K Hosohata, et al.Life Sciences|February 24, 2001
Biological properties of Phe(o)-opioid peptide analoguesA W Lipkowski, A Misicka, K Hosohata, et al.International Journal of Peptide and Protein Research|July 1, 1993
Synthetic linear and cyclic glucagon antagonistsR Dharanipragada, D Trivedi, A Bannister, et al.Journal of Medicinal Chemistry|January 7, 1994
Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptorsA Misicka, A W Lipkowski, R Horvath, et al.Biochimica Et Biophysica Acta|August 17, 1984
Metabolic effects and cyclic AMP levels produced by glucagon, (1-N alpha-Trinitrophenylhistidine,12-homoarginine)glucagon and forskolin in isolated rat hepatocytesS Corvera, J Huerta-Bahena, J T Pelton, et al.Life Sciences|January 1, 1996
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical studyR T Dorr, R Lines, N Levine, et al.Pageof 72